Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

CME Credit Available: Maximum of 6 AMA PRA Category 1 Credits™
Release Date: July 21, 2011
Expiration Date: July 22, 2012

This activity consists of audio and visual recording of 9 live presentations with Question-and-Answer. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• Design antiretroviral strategies that consider current data on early and late regimen failure
• Describe the role of immune activation as it relates to HIV progression
• Explain the key issues and treatment implications associated with HIV and disability, delayed progression in HIV-infected patients, and cardiovascular complications of HIV disease
• Describe new data on pre-exposure prophylaxis
• Identify current treatment challenges in HIV care as they relate to the aging population
• Describe current data on investigational hepatitis C virus drugs as they impact the potential for treatment
• Formulate appropriate management strategies for HIV patients with advanced liver disease
  

CME Credit

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this internet enduring material activity for a maximum of 6 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Webcast Faculty

Chairs

John P. Phair, MD
Course Chair
Professor of Medicine, Emeritus
Feinberg School of Medicine
Division of Infectious Diseases
Northwestern University
Chicago, Illinois

Paul A. Volberding, MD
Course Vice-Chair
Member, Board of Directors (Volunteer)
IAS–USA
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans Affairs Medical Center
San Francisco, California

Speakers

Connie L. Celum, MD, MPH
Professor of Global Health and Medicine
University of Washington
Seattle, Washington

Joseph B. Margolick, MD, PhD
Professor of Molecular Microbiology
and Immunology
The Johns Hopkins Bloomberg
School of Public Health
Baltimore, Maryland

Susanna Naggie, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham Veterans Affairs Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Wendy S. Post, MD
Associate Professor of Medicine
and Epidemiology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Benigno Rodriguez, MD
Assistant Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio

Michael S. Saag, MD
Member, Board of Directors (Volunteer)
IAS–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio



Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the IAS–USA requires all persons with control of content (ie; faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. (Updated 03/01/11)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. (Updated 03/04/11)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp (now Merck & Co, Inc), and Sanofi Pasteur. (Updated 03/01/11)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, and ViiV Healthcare. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc. (Updated 03/01/11)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, MedImmune, LLC; Merck & Co, Inc, ViiV Healthcare, and ViroStatics, and as an investigator for research study grants (to Weill Cornell) from Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. (Updated 3/4/11)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/10/11)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc. He has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc. (Updated 03/01/11)

Michael S. Saag, MD
Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 06/10/11)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, Johnson & Johnson Services, Inc, Merck & Co, Inc, Santaris Pharma, Tobira Therapeutics, and Laboratory Corporation of America. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 05/12/11)

Paul A. Volberding, MD
Dr Volberding has served as a consultant to or on scientific or clinical advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc, Merck & Co, Inc, and TaiMed Biologics. (Updated 06/09/11)

Course Faculty and Staff

Dr Celum has received grants and research support from GlaxoSmithKline and served as a scientific advisor for Merck & Co, Inc, and an unpaid scientific advisor for Gilead Sciences, Inc. (Updated 06/10/11)

Dr Lederman has received grants and research support from Cytheris and Pfizer Inc. He has served as a consultant to Argos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co, Inc, and Sangamo Biosciences, Inc. (Updated 06/10/11)

Dr Margolick has received research support from Tibotec Therapeutics. (Updated 06/02/11)

Dr Naggie has served as a scientific advisor to and/or on advisory boards for Vertex Pharmaceuticals, Inc. She has received grants and research support from Synexis Inc, and Vertex Pharmaceuticals, Inc. (Updated 06/10/11)

Dr Phair has served on data and safety monitoring boards for Pfizer Inc. (Updated 06/10/11)

Dr Post has no relevant financial affiliations to disclose. (Updated 06/10/11)

Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 06/10/11)

Dr Sherman has served as a consultant or scientific advisor to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Inc, Regulus, SciClone, Three Rivers, and Vertex Pharmaceuticals, Inc. He has served on data and safety monitoring boards and endpoint adjudication committees for MedPace, Pfizer Inc, and Tibotec Therapeutics. He received fees or royalties for written enduring materials, internet activities, and audiovisual activities from UpToDate. (Updated 06/09/11)

Dr Volberding has served as a consultant to or on scientific or clinical advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc, Merck & Co, Inc, and TaiMed Biologics. (Updated 06/09/11)


IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Associate, has no relevant financial affiliations to disclose. (Updated 06/10/11)

Grant Support

This Webcast activity is sponsored by the IAS–USA.

Funding for this Webcast and on the live activity which this Webcast was based came from the following commercial companies:

MAJOR SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc

SUBSTANTIAL SUPPORTERS
Bristol-Myers Squibb
Tibotec Therapeutics

GENEROUS SUPPORTERS
Abbott Laboratories
ViiV Healthcare

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the IAS–USA:

IAS–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2011@iasusa.org

I have read these instructions and understand them.